FDA Inspection 1006668 — Hetero USA Inc
The FDA completed an inspection of Hetero USA Inc on Mar 17, 2017 in Piscataway, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 3 citations were issued during this inspection. Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Mar 17, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Piscataway, NJ (United States)
Additional details
Postmarket Adverse Drug Experience (PADE)
Citations
| ID | CFR | Description |
|---|---|---|
| 6730 | 21 CFR 314.80(b) | Failure to develop written procedures |
| 6731 | 21 CFR 314.80(c) | [NDA prod] Fail to submit report in apprvd electronic format |
| 6831 | 21 CFR 314.80(c)(2) | Late submission of quarterly safety reports |